Cited 0 time in
Cited 0 time in
Dehydroevodiamine center dot HCl Protects Against Memory Impairment and Cerebral Amyloid-beta Production in Tg2576 Mice by Acting as a beta-Secretase Inhibitor
- Dehydroevodiamine center dot HCl Protects Against Memory Impairment and Cerebral Amyloid-beta Production in Tg2576 Mice by Acting as a beta-Secretase Inhibitor
- Shin, KY[Shin, Ki Young]; Noh, SJ[Noh, Su-Jin]; Park, CH[Park, Cheol Hyoung]; Jeong, YH[Jeong, Yun Ha]; Chang, KA[Chang, Keun-A]; Yoo, J[Yoo, Jakyung]; Kim, HJ[Kim, Hee Jin]; Ha, S[Ha, Sungji]; Kim, HS[Kim, Hye-Sun]; Park, HJ[Park, Hyun-Ju]; Lee, JH[Lee, Jun-Ho]; Moon, C[Moon, Cheil]; Suh, YH[Suh, Yoo-Hun]
- DGIST Authors
- Moon, C[Moon, Cheil]
- Issue Date
- CNS and Neurological Disorders: Drug Targets, 15(8), 935-944
- Article Type
- Alzheimer' s Disease (AD); Beta-Secretase; Dehydroevodiamine?Hcl; Inhibitor; Memory
- We previously demonstrated that dehydroevodiamine•HCl (DHED), which was purified from Evodia rutaecarpa Bentham (Rutaceae), has beneficial effects on memory impairment and neuronal damage in three disease models. To investigate the preventive action of DHED in Alzheimer’s disease (AD), a progressive neurodegenerative disorder characterized by memory decline, amyloid-β (Aβ) protein-containing neuritic plaques and neurofibrillary tangles, in this study, we proposed that DHED may be therapeutically effective against the memory impairment and disease-related neurochemical changes that occur in Tg2576 (Tg) mice. DHED (0.5 mg/kg) was intraperitoneally administered to 7-month-old Tg and wild type mice for 4 months. In passive avoidance and water maze tests, DHED improved memory impairment of Tg mice after 4 months of administration. DHED also reduced cortical levels of soluble Aβ40, soluble Aβ42 and total Aβ peptides in the Tg mice. Additionally, we investigated whether DHED may be a β-secretase inhibitor that affects the production of Aβ related to the formation of neuritic plaques. DHED directly inhibited β-secretase activity in a concentrationdependent manner. The concentration required for 50 % enzyme inhibition (IC50) was 40.96 µM, and DHED may act as a competitive inhibitor of β-secretase. Moreover, DHED interacted strongly with BACE1 (β-secretase 2QP8), as demonstrated in the analysis of the binding mode of DHED in the active site of human BACE1. In conclusion, DHED may exhibit therapeutic effects for AD as a β-secretase inhibitor. © 2016 Bentham Science Publishers.
- Bentham Science Publisher
- Related Researcher
There are no files associated with this item.
- Brain and Cognitive SciencesETC1. Journal Articles
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.